TUDCA has accumulated a diverse body of evidence spanning liver disease, neurodegenerative conditions, and metabolic disorders. This page organizes the evidence by therapeutic area and rates the strength of evidence for each claimed benefit. All claims are sourced from peer-reviewed, PubMed-indexed research.
The liver is the organ where TUDCA concentrations are highest following oral administration, and it is where the most consistent clinical evidence exists. Three primary mechanisms drive TUDCA's hepatoprotective effect: (1) displacement of toxic hydrophobic bile acids from the hepatocellular bile acid pool, (2) direct anti-apoptotic protection of hepatocytes and cholangiocytes, and (3) stimulation of bile flow (choleresis) to reduce intrahepatic bile acid stasis.
A 3-month open-label clinical trial in patients with chronic hepatitis (mixed etiology) demonstrated that TUDCA supplementation produced statistically significant reductions in ALT, AST, and GGT compared to baseline values. Mean ALT decreased by approximately 35–50% in treatment-compliant subjects. Preclinical evidence extends to cholestatic models, where TUDCA reduced hepatocellular necrosis by 60–80% in bile duct-ligated rodents, and to alcoholic and non-alcoholic fatty liver disease models.
For primary biliary cholangitis (PBC), the FDA-approved agent is TUDCA's parent compound UDCA at 13–15 mg/kg/day. TUDCA studies in PBC are smaller but suggest comparable or slightly superior biochemical response rates due to higher bioavailability of the conjugated form. See TUDCA for Liver Health for a comprehensive analysis.
TUDCA's ability to cross the blood-brain barrier distinguishes it from UDCA and is the basis for investigation across neurodegenerative diseases. The evidence is strongest at the preclinical level; human data remain limited to one ALS pilot trial.
A single-center pilot trial (Elia et al., 2016) enrolled 34 ALS patients and administered TUDCA 1 g twice daily. The regimen was well-tolerated over 54 weeks. Patients receiving TUDCA showed a slower rate of functional decline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to matched historical controls. However, a subsequent multicenter Phase 3 trial (TUDCA-ALS, NCT03800524, n=336) completed in 2024 and did not meet its primary endpoint; ALSFRS-R decline, survival, and neurofilament light levels did not differ significantly between TUDCA and placebo. This negative Phase 3 result substantially weakens the evidence for TUDCA in ALS, though subgroup analyses of slow versus fast progressors are ongoing.
In APP/PS1 transgenic mice, 6 months of TUDCA treatment reduced amyloid-beta plaque burden in the hippocampus by approximately 35% and in the cortex by approximately 40%. Behavioral correlates included significantly improved freezing behavior in contextual fear conditioning (a hippocampus-dependent memory task) and shorter escape latencies in the Morris water maze. TUDCA's mechanism in Alzheimer's models involves both anti-apoptotic protection of existing neurons and reduction of Aβ-induced ER stress in the unfolded protein response pathway.
In MPTP-treated mice (a model of dopaminergic neurodegeneration), TUDCA administration preserved approximately 50–65% of tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta compared to vehicle-treated controls. Striatal dopamine levels, measured by HPLC, were correspondingly preserved. In the 6-OHDA rat model, TUDCA reduced apomorphine-induced rotational behavior by approximately 40%, indicating functional preservation of the nigrostriatal pathway. Microglial activation markers (CD68, Iba-1) were reduced in TUDCA-treated animals, implicating an anti-neuroinflammatory mechanism.
Kars et al. (2010) conducted a double-blind, randomized, placebo-controlled trial administering TUDCA 1,750 mg/day for 4 weeks to 20 obese subjects (BMI approximately 35 kg/m²). Liver insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp with stable isotope tracer, improved by approximately 30% (p = 0.02 vs. placebo). Muscle insulin sensitivity increased by approximately 25%. Adipose tissue insulin sensitivity did not change significantly. Importantly, these effects occurred without weight loss, suggesting a direct metabolic mechanism independent of body composition changes. Follow-up research suggests this effect is mediated through ER stress reduction in hepatocytes and myocytes.
Additional areas with preclinical or early clinical signals include: retinal degeneration (photoreceptor protection in RP models), cardiac ischemia-reperfusion injury (reduced infarct size in rodent models), and inflammatory bowel disease (reduced colitis severity scores in murine DSS colitis). None of these indications have advanced beyond phase I/II.
| Condition | Evidence Level | Key Findings |
|---|---|---|
| Chronic Hepatitis / Liver Injury | Clinical Trial (small) | ALT, AST, GGT reduced by 35–50% over 3 months. Open-label design; no large RCT. |
| ALS | Clinical Trial (Phase 3 negative) | Pilot (n=34) showed slower decline at 1 g BID. Phase 3 (n=336, 2024) did not meet primary endpoint. |
| Insulin Resistance / T2DM | Clinical Trial (RCT) | Hepatic + muscle insulin sensitivity improved ~30%. n=20, 4-week study. |
| Alzheimer's Disease | Preclinical (animal models) | Reduced Aβ plaques ~35–40% in mice. Memory improvement on behavioral tests. No human trials. |
| Parkinson's Disease | Preclinical (animal models) | Preserved ~50–65% of dopaminergic neurons in MPTP model. Reduced neuroinflammation. No human trials. |
| NAFLD / NASH | Preclinical + Limited Clinical | Reduced steatosis and ALT in animal models. Human data limited to surrogate markers. |
| Retinal Degeneration | Preclinical (animal models) | Photoreceptor preservation in RP models. No human data. |
Evidence Level definitions: Clinical Trial (RCT) = randomized, placebo-controlled; Clinical Trial (small/pilot) = non-randomized or underpowered; Preclinical = cell culture or animal models only. Table reflects published literature as of July 2026.